ATE316957T1 - Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate - Google Patents

Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate

Info

Publication number
ATE316957T1
ATE316957T1 AT02722569T AT02722569T ATE316957T1 AT E316957 T1 ATE316957 T1 AT E316957T1 AT 02722569 T AT02722569 T AT 02722569T AT 02722569 T AT02722569 T AT 02722569T AT E316957 T1 ATE316957 T1 AT E316957T1
Authority
AT
Austria
Prior art keywords
intermediate products
compounds usable
aminoquinoline derivatives
aminoquinoline
derivatives
Prior art date
Application number
AT02722569T
Other languages
English (en)
Inventor
David B Damon
Robert Wayne Dugger
Robert William Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE316957T1 publication Critical patent/ATE316957T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02722569T 2001-04-30 2002-04-08 Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate ATE316957T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
ATE316957T1 true ATE316957T1 (de) 2006-02-15

Family

ID=23103272

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02722567T ATE321755T1 (de) 2001-04-30 2002-04-08 Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren
AT02722569T ATE316957T1 (de) 2001-04-30 2002-04-08 Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02722567T ATE321755T1 (de) 2001-04-30 2002-04-08 Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren

Country Status (24)

Country Link
US (3) US6600045B2 (de)
EP (2) EP1425270B1 (de)
JP (2) JP3924250B2 (de)
KR (2) KR100591998B1 (de)
CN (3) CN1267411C (de)
AR (3) AR036331A1 (de)
AT (2) ATE321755T1 (de)
AU (1) AU2002253448B2 (de)
BR (2) BR0209291A (de)
CA (2) CA2445623A1 (de)
CZ (2) CZ20032898A3 (de)
DE (2) DE60210265T2 (de)
DK (2) DK1425270T3 (de)
ES (2) ES2259080T3 (de)
HU (2) HU225777B1 (de)
IL (2) IL157546A0 (de)
MX (2) MXPA03009935A (de)
PL (2) PL366700A1 (de)
PT (1) PT1425270E (de)
RU (2) RU2259355C2 (de)
TW (1) TWI250974B (de)
WO (2) WO2002088085A2 (de)
YU (2) YU84403A (de)
ZA (2) ZA200306599B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2004032848A2 (en) * 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2006513186A (ja) 2002-12-20 2006-04-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
JP4644658B2 (ja) 2003-02-18 2011-03-02 高砂香料工業株式会社 光学活性テトラヒドロキノリン類の製造方法
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
BRPI0407954A (pt) * 2003-03-17 2006-03-07 Kaneka Corp processo para a produção de derivado de amida de ácido (r)-3-[4-(trifluorometil) fenilamino]-pentanóico
MXPA06003357A (es) 2003-09-26 2006-06-08 Japan Tobacco Inc Metodo para inhibir la produccion de lipoproteina remanente.
DE602004023100D1 (de) * 2003-10-08 2009-10-22 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidemie
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
CA2561564A1 (en) * 2004-04-07 2005-10-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
WO2006091674A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
MX2007016093A (es) * 2005-06-20 2008-03-10 Astrazeneca Ab Proceso para la produccion de sulfonatos de (alcoxicarbonilamino)- alquilo.
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
HRP20170422T1 (hr) 2011-04-12 2017-06-16 Chong Kun Dang Pharmaceutical Corp. 3-(2-aril-cikloalkenilmetil)-oksazolidin-2-on derivati kao inhibitori transportnog proteina estera kolesterola (cetp)
SG10201605304VA (en) * 2011-07-08 2016-08-30 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
ES2642172T3 (es) 2013-01-31 2017-11-15 Chong Kun Dang Pharmaceutical Corp. Compuestos derivados de ciclohexeno sustituidos con biarilo o biarilo heterocíclico como inhibidores de CETP
CN105706289A (zh) * 2013-11-11 2016-06-22 隆萨有限公司 利用路易斯酸制备第13族元素的氰基化合物的方法
ES2926775T3 (es) * 2014-08-12 2022-10-28 Newamsterdam Pharma B V Proceso de preparación de intermedios sintéticos para la preparación de derivados de tetrahidroquinolina
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205037B (de) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
CA2336691C (en) 1998-07-10 2009-02-10 Massachusetts Institute Of Technology Ligands for metals and metal-catalyzed processes
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
US20030073843A1 (en) 2003-04-17
MXPA03009936A (es) 2004-01-29
HUP0304039A3 (en) 2005-10-28
WO2002088085A2 (en) 2002-11-07
HU225777B1 (en) 2007-08-28
EP1425270B1 (de) 2006-03-29
DE60210265D1 (de) 2006-05-18
WO2002088069A2 (en) 2002-11-07
JP3924251B2 (ja) 2007-06-06
EP1383734A2 (de) 2004-01-28
US20020177716A1 (en) 2002-11-28
CN1297541C (zh) 2007-01-31
WO2002088085A3 (en) 2004-03-25
CN1529696A (zh) 2004-09-15
JP2004531541A (ja) 2004-10-14
AR035963A1 (es) 2004-07-28
ES2259080T3 (es) 2006-09-16
CZ20032900A3 (cs) 2004-06-16
YU84303A (sh) 2006-05-25
AR036331A1 (es) 2004-09-01
BR0209238A (pt) 2004-06-15
RU2265010C2 (ru) 2005-11-27
MXPA03009935A (es) 2004-01-29
DK1383734T3 (da) 2006-05-15
CN1267411C (zh) 2006-08-02
TWI250974B (en) 2006-03-11
PL366700A1 (en) 2005-02-07
US6600045B2 (en) 2003-07-29
ES2256461T3 (es) 2006-07-16
EP1425270A2 (de) 2004-06-09
KR100591998B1 (ko) 2006-06-22
CZ20032898A3 (cs) 2004-07-14
CN1680292A (zh) 2005-10-12
EP1383734B1 (de) 2006-02-01
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
AR044706A2 (es) 2005-09-21
PL366584A1 (en) 2005-02-07
HUP0304041A3 (en) 2005-08-29
KR100639745B1 (ko) 2006-10-30
CN1505609A (zh) 2004-06-16
CA2445623A1 (en) 2002-11-07
US6689897B2 (en) 2004-02-10
WO2002088069A3 (en) 2003-02-20
DK1425270T3 (da) 2006-07-03
JP3924250B2 (ja) 2007-06-06
YU84403A (sh) 2006-08-17
US20030216576A1 (en) 2003-11-20
RU2003131870A (ru) 2005-01-27
CA2445693A1 (en) 2002-11-07
ATE321755T1 (de) 2006-04-15
HUP0304041A2 (hu) 2004-04-28
HK1062294A1 (en) 2004-10-29
IL157546A0 (en) 2004-03-28
ZA200306600B (en) 2004-08-25
KR20040015200A (ko) 2004-02-18
DE60210265T2 (de) 2006-10-12
BR0209291A (pt) 2004-07-13
IL157544A0 (en) 2004-03-28
AU2002253448B2 (en) 2007-07-05
DE60209004T2 (de) 2006-09-28
CN100357265C (zh) 2007-12-26
ZA200306599B (en) 2004-10-22
WO2002088069A9 (en) 2003-12-04
DE60209004D1 (de) 2006-04-13
RU2003131871A (ru) 2005-04-10
PT1425270E (pt) 2006-07-31
HUP0304039A2 (hu) 2004-03-29
JP2004527556A (ja) 2004-09-09
US6706881B2 (en) 2004-03-16

Similar Documents

Publication Publication Date Title
ATE316957T1 (de) Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate
ATE387428T1 (de) Chinolinderivate als liganden für den neuropeptid-y-rezeptor
ATE397926T1 (de) Glukokinase beeinflussende verbindungen
NO20033579L (no) Fremgangsmåte for syntetisering av camptothecin relaterte forbindelser
DE60316278D1 (de) Packung für rauchartikel
ATE335426T1 (de) Ausziehführungsgarnitur für schubladen
DK1412328T3 (da) Dolastatin-10-derivater
DE60317711D1 (de) Kationische porphyrin-derivate als antibakterielle mittel
DE60206017D1 (de) Abdeckung für bohrlochfilter
ATE335477T1 (de) Indolylalkylamin-derivate als 5-hydroxytryptamin- 6 liganden
DE60206652D1 (de) Benzothiazolderivate als adenosin-rezeptor-liganden
DE60317684D1 (de) SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
DE602004028821D1 (de) Pyrrolidiniumderivative als liganden für den muscarinen m3-rezeptor
DE60222582D1 (de) Grundiermittel für polyolefinmaterialien
IS7288A (is) Aðferðir til að hreinsa levófloxasín
ATE405574T1 (de) Aryl-annellierte azapolyzyklische verbindungen
DE50206910D1 (de) Substituierte y-lactonverbindungen als nmda-antagonisten
DE60141920D1 (de) Etagentür für aufzug
DE50115802D1 (de) Dafür
SK3446U (sk) Kompenzátor pre chemický priemysel
ATA2252002A (de) Ladentheke
DE60219659D1 (de) Heterocyclische retioidverbindungen
SE0102339D0 (sv) Process for bulk autoclaving
UA5408S (uk) Наличка до штанів
ITAQ20020001U1 (it) Si presenta contemporaneamente domanda per invenzione industriale ai sensi dell'art. 4 r.d.1411/40

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1383734

Country of ref document: EP

REN Ceased due to non-payment of the annual fee